Table 2.

Incidence of AEs during the double‐blind period by preferred term

Preferred term	Sacubitril/valsartan 200 mgn = 18	Olmesartan 20 mgn = 18
Deaths	0 (0)	0 (0)
Any serious AEs	0 (0)	2 (1.1)
Benign neoplasm of thyroid gland	0 (0)	1 (0.5)
Cerebrovascular accident	0 (0)	1 (0.5)
Discontinuations during double‐blind period
AEs discontinuations	2 (1.1)	5 (2.7)
Drug‐related AEs discontinuations	0 (0)	2 (1.1)
Serious AE discontinuations	0 (0)	1 (0.5)
Any AEsa	44 (23.4)	41 (21.9)
Headache	5 (2.7)	6 (3.2)
Arthralgia	3 (1.6)	0 (0)
Blood bilirubin increased	2 (1.1)	0 (0)
Bronchitis	2 (1.1)	0 (0)
Dizziness	2 (1.1)	4 (2.1)
Hypotension	2 (1.1)	2 (1.1)
Local swelling	2 (1.1)	0 (0)
Nasopharyngitis	2 (1.1)	1 (0.5)
Cough	1 (0.5)	2 (1.1)
Myalgia	1 (0.5)	2 (1.1)
Abdominal pain upper	0 (0)	2 (1.1)

Data are presented as number (percentage).

^aOf all adverse events (AEs), only those with an incidence rate of ≥2 patients in any of the treatment group are mentioned.